Cargando…
Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919153/ https://www.ncbi.nlm.nih.gov/pubmed/35286479 http://dx.doi.org/10.1007/s00415-022-11053-7 |
| _version_ | 1784668892394684416 |
|---|---|
| author | Allman, M. Tallantyre, E. Robertson, N. P. |
| author_facet | Allman, M. Tallantyre, E. Robertson, N. P. |
| author_sort | Allman, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8919153 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89191532022-03-14 Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies Allman, M. Tallantyre, E. Robertson, N. P. J Neurol Journal Club Springer Berlin Heidelberg 2022-03-14 2022 /pmc/articles/PMC8919153/ /pubmed/35286479 http://dx.doi.org/10.1007/s00415-022-11053-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Journal Club Allman, M. Tallantyre, E. Robertson, N. P. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies |
| title | Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies |
| title_full | Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies |
| title_fullStr | Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies |
| title_full_unstemmed | Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies |
| title_short | Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies |
| title_sort | response to sars-cov-2 vaccination in multiple sclerosis patients on disease modifying therapies |
| topic | Journal Club |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919153/ https://www.ncbi.nlm.nih.gov/pubmed/35286479 http://dx.doi.org/10.1007/s00415-022-11053-7 |
| work_keys_str_mv | AT allmanm responsetosarscov2vaccinationinmultiplesclerosispatientsondiseasemodifyingtherapies AT tallantyree responsetosarscov2vaccinationinmultiplesclerosispatientsondiseasemodifyingtherapies AT robertsonnp responsetosarscov2vaccinationinmultiplesclerosispatientsondiseasemodifyingtherapies |